.jpg)
OUR MISSION
Our mission is to harness the therapeutic potential of the MOR signaling pathway in oncology and severe illness.
Glycyx has a simple premise, when a core biological mechanism needed for acute response to injury is activated chronically, it prevents immune infiltration into tumors.
Chronic activation accelerates disease progression and mortality in many severe illnesses.
Our lead is a novel oral, small molecule, MOR antagonist. The MOR pathway has complementary mechanisms in oncology, with direct tumor effects, and broad activity across multiple immune cell types. Our lead compound has previous Phase 2b data with effective target engagement and good safety and tolerability.
AXELOPRAN
• Enables immune infiltration into tumors with minimal toxicity and adverse side effects
• Potent small molecule with easy oral dosing
• 9 clinical studies through Phase 2b
• Pre-clinical proof of concept in multiple cancers
• Active IND; CMC ready for 12kg CTM batches
• IP multi-tiered through 2042+
OUR IMPACT
Axelopran turns cold tumors hot
-
Tumors can hijack the natural injury response mechanism, co-opting the healing process to grow and hide
-
Axelopran is a breakthrough cancer therapy that blocks the injury response pathway turning cold tumors hot by enabling immune infiltration of the tumor microenvironment
-
In pre-clinical models axelopran reduces tumor growth and tumor metastasis and increases T-cell and NK cell infiltration
-
Potential to double response rates of immune checkpoint inhibitors for both overall survival and progression free survival
